Wedbush has increased the price target on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) from $74 to $84 while reiterating the Neutral rating. BioMarin reported three-year…
Wedbush analyst Seth Basham reiterated an Underperform rating on the shares of Bed Bath & Beyond Inc (NASDAQ: BBBY) and lowered the price target from $5 to $1.
Commvault Systems, Inc (NASDAQ:CVLT) negatively preannounced Q3 results, missing KeyBanc analyst Thomas Blakey’s revenue estimate, resulting in a miss to EPS…